Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.
The overall response rate was 50%, with a complete response rate of 32%.
The custom immunotherapy is now indicated for adults with relapsed or refractory lymphoma.
Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.
FDA grants regular approval to obinutuzumab (Gazyva) for adults with previously untreated follicular lymphoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.